Conference Proceedings

Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

MR Stockler, AJ Martin, H Dhillon, ID Davis, KN Chi, S Chowdhury, LG Horvath, NJ Lawrence, GM Marx, J Mc Caffrey, R McDermott, SA North, F Parnis, DW Pook, MN Reaume, SK Sandhu, TH Tan, A Thomson, R Zielinski, CJ Sweeney

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

Grants

Funding Acknowledgements

Astellas Pharma.